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Vaccines are the most efficient and cost-effective means of preventing infectious disease.
However, traditional vaccine approaches have thus far failed to provide protection against
human immunodeficiency virus (HIV), tuberculosis, malaria, and many other diseases.
New approaches to vaccine development are needed to address some of these intractable
problems. In this report, we review the literature identifying stimulatory effects of
mesenchymal stem cells (MSC) on immune responses and explore the potential for
MSC as a novel, universal vaccination platform. MSC are unique bone marrow-derived
multipotent progenitor cells that are presently being exploited as gene therapy vectors
for a variety of conditions, including cancer and autoimmune diseases. Although MSC are
predominantly known for anti-inflammatory properties during allogeneic MSC transplant,
there is evidence that MSC can actually promote adaptive immunity under certain settings.
MSC have also demonstrated some success in anti-cancer therapeutic vaccines and
anti-microbial prophylactic vaccines, as we report, for the first time, the ability of modified
MSC to express and secrete a viral antigen that stimulates antigen-specific antibody
production in vivo. We hypothesize that the unique properties of modified MSC may
enable MSC to serve as an unconventional but innovative, vaccine platform. Such a
platform would be capable of expressing hundreds of proteins, thereby generating a broad
array of epitopes with correct post-translational processing, mimicking natural infection.
By stimulating immunity to a combination of epitopes, it may be possible to develop
prophylactic and even therapeutic vaccines to tackle major health problems including those
of non-microbial and microbial origin, including cancer, or an infectious disease like HIV,
where traditional vaccination approaches have failed.
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INTRODUCTION
While vaccination programs have clear documented success in
controlling many diseases, there has been a failure to generate
effective, long-term immunity against certain major pathogens.
On the other hand, in carcinogenic situations there is an urgent
need to develop therapies that promote the host immune sys-
tem to target and destroy cancerous tumors and metastases.
Mesenchymal stem cells (MSC) are unique bone marrow-derived
multipotent progenitor cells that are presently being exploited as
gene therapy vectors for a variety of conditions, including can-
cer and autoimmune diseases (Klopp et al., 2007; Le Blanc and
Ringden, 2007; Spaeth et al., 2008; Bergfeld and Declerck, 2010;
Chen et al., 2010; Liang et al., 2010; Martino et al., 2010; Panes
et al., 2010). Although MSC are predominantly known for anti-
inflammatory properties during allogeneic MSC transplant, there
is evidence that MSC can actually promote adaptive immunity
under certain settings. We hypothesize that the unique properties
of modified MSC may enable these cells to serve as an unconven-
tional but innovative, vaccine platform (described in Figure 1A).
Such a platform would be capable of expressing hundreds of pro-
teins, thereby generating a broad array of epitopes with correct
post-translational processing, mimicking natural infection. In
this report, we review the literature supporting our hypothesis by
identifying stimulatory effects of MSC on immune responses and
demonstrate, as proof of concept, the ability of modified MSC to
express and secrete a viral antigen that stimulates antigen-specific
antibody production in vivo.
CURRENT PROBLEMS IN VACCINATION STRATEGIES
THE IDEAL VACCINE
Vaccines are the most efficient and cost-effective means of pre-
venting infectious disease. Vaccines have already demonstrated
transformative potential in eradicating one devastating disease,
smallpox, while offering the ability to control other diseases,
including diphtheria, polio, and measles, that formerly caused
widespread morbidity and mortality. The development of vac-
cines involves the testing of an attenuated or inactivated version of
the pathogen or identification of a pathogen component(s) (i.e.,
subunit, toxoid, and virus-like particle) that elicits an immune
response that protects recipients from disease when they are
exposed to the actual pathogen. In an ideal world a single vaccine
would be able to target all major human pathogens (versatile),
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FIGURE 1 | Strategy of modified MSC vaccination and possible MSC
functions during vaccination. (A) MSC isolated from the bone marrow of
human donors can be expanded in culture and modified by transfection using
antigen(s)-encoding plasmid to express and secrete soluble proteins,
including both cancer and microbial antigens. Parenteral immunization of
these modified MSC could then provide protective immunity. (B) These
modified MSC may carry out several possible functions after vaccination.
Primarily, it is expected that they serve as antigen delivery vehicles or even
antigen depots following immunization. Based on the literature, it is clear that
MSC can also take a more active role in induction of adaptive immunity,
including cytokine secretion, like IL-6, and/or antigen presentation through
phagocytosis and MHC-loading of antigen for presentation to lymphocytes
expressing cognate T-cell/B-cell receptors. These immunostimulatory
functions may also be involved in MSC-based vaccinations.
elicit strong protective immunity to these pathogens (robust)
without inducing unwanted side-effects (safe), and still be fairly
inexpensive to produce per dose (cost-effective). In the case of
viruses or host-cell produced proteins, vaccine production that
includes human post-translational processing, mimicking natu-
ral infection, will likely prove to be superior to bacterial or other
expression systems.
FAILURES OF TRADITIONAL STRATEGIES
Traditional vaccine approaches have thus far failed to provide
protection against human immunodeficiency virus (HIV), tuber-
culosis, malaria, and many other diseases, including dengue,
herpes, and even the common cold. The reasons why traditional
vaccine approaches have not been successful for these diseases
are complex and varied. For example, HIV integrates functional
proviral genomes into the DNA of host cells, thereby establish-
ing latency or persistence. Once latency/persistence is established,
it has not been possible to eradicate HIV, even with highly
active antiretroviral therapy. Clearly, new approaches to vaccine
development are needed to address HIV and other intractable
vaccine challenges.
NON-TRADITIONAL VACCINE STRATEGIES
Newer alternative immunization approaches include both DNA
and cellular vaccines. DNA vaccines involve the transfection of
cells at the tissue site of vaccination with an antigen encoding
plasmid that allows local cells (i.e., myocytes) to produce the vac-
cine antigen in situ. Cellular vaccines use the direct transfer of
pre-pulsed or transfected host cells [i.e., dendritic cells (DC)]
expressing or presenting the vaccine antigen. The advantage of
these approaches is that vaccine antigens are produced in vivo
and are readily available for immunological processing. Despite
numerous reports of successful pre-clinical testing, both such
approaches have hit stumbling blocks. DNA vaccination studies
in humans show poor efficacy, which was linked to innate differ-
ences between mice and humans (Cavenaugh et al., 2011; Wang
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et al., 2011). DC vaccination strategies have shown limited clin-
ical success for therapeutic cancer vaccinations and have high
production costs due to necessary individual tailoring (Bhargava
et al., 2012; Palucka and Banchereau, 2012).
MSC-BASED CELLULAR THERAPEUTICS
MSC are unique bonemarrow-derivedmultipotent stem cells that
are presently being exploited as gene therapy vectors for a variety
of conditions, including cancer and autoimmune diseases (Klopp
et al., 2007; Le Blanc and Ringden, 2007; Spaeth et al., 2008;
Bergfeld and Declerck, 2010; Liang et al., 2010; Lim et al., 2010;
Martino et al., 2010; Panes et al., 2010). These progenitor cells
are known to migrate to sites of inflammation, infection, tissue
injury, and tumors where they immunomodulate the microen-
vironment through cell-to-cell contact and the release of soluble
factors, thus facilitating the repair of damaged tissue (Aggarwal
and Pittenger, 2005; Gotherstrom, 2007). For more information
see recent reviews on the immunomodulatory properties of MSC
therapy (Le Blanc and Ringden, 2007; Stagg, 2007; Tolar et al.,
2007; Franquesa et al., 2012; Yi and Song, 2012).
A main contributing factor to therapeutics designed around
MSC is the ease of MSC isolation and expansion in culture.
Theoretically, a single bone marrow harvest of MSC may yield
sufficient MSC for thousands of clinical applications, due to
their inherent expansion capability (Newman et al., 2009). Such
expansion potential greatly enhances the GMP manufacturing
capability of using MSC for clinical applications and has lower
production costs when compared to other cell types.
MSC have been successfully transplanted into allogeneic hosts
in a variety of clinical and pre-clinical settings (Di Nicola et al.,
2002; Meisel et al., 2004; Aggarwal and Pittenger, 2005; Chen
et al., 2006; Corcione et al., 2006; Sotiropoulou et al., 2006; Uccelli
et al., 2007; Raffaghello et al., 2008). These donor MSC often
promote immunotolerance (Potian et al., 2003; Aggarwal and
Pittenger, 2005), including the inhibition of graft-versus-host dis-
ease (GvHD) that can develop after cell or tissue transplantation
from a major histocompatibility complex (MHC)-mismatched
donor (Ringden et al., 2006; Wernicke et al., 2011). The dimin-
ished GvHD symptoms after MSC transfer has been due to direct
MSC inhibition of T and B cell proliferation, resting natural killer
cell cytotoxicity, and DC maturation (reviewed in Uccelli et al.,
2008). Although, in contrast, at least one study has reported
generation of antibodies against transplanted allogeneic MSC
(Sundin et al., 2007). Nevertheless, the ability to prevent GvHD
also suggests that MSC expressing foreign antigen might have
an advantage over other cell types (i.e., DC) during a cellular
vaccination in selectively inducing immune responses to only
the foreign antigen(s) expressed by MSC and not specifically
the donor MSC. Thereby, MSC as the cellular base for an alter-
native vaccination strategy may save on production time and
costs associated with necessary HLA matching if other cell types
were used.
In order to enhance their immunomodulatory properties, the
use of modified MSC is also being explored in vivo (Choi et al.,
2008; Sasaki et al., 2009; Kumar et al., 2010; Klinge et al., 2011).
MSC can be easily transfected with protein encoding plasmids,
for transient protein expression or a more long-term, stable
transfection and prolonged protein expression. MSC, transduced
to overproduce IL-10, suppressed collagen-induced arthritis in a
mouse model (Choi et al., 2008). In addition, MSC expressing
glucagon-like peptide-1 transplanted into an Alzheimer’s dis-
ease mouse model led to a decrease in A-beta deposition in the
brain (Klinge et al., 2011). In an osteopenia mouse model, mice
receiving transduced MSC that had stable expression of bone
morphogenetic protein had increased bone density (Kumar et al.,
2010). In a rat model for spinal cord injury, rats treated with
MSC stably overexpressing of brain-derived neurotrophic fac-
tor had a better overall outcome than rats administered MSC
alone (Sasaki et al., 2009). Lastly, in a rat model for bladder
outlet obstruction, rats receiving transduced MSC with stable
overexpression of hepatocyte growth factor had decreased col-
lagen accumulation in the bladder (Song et al., 2012). These
studies indicate that modified MSC are a useful and feasible vehi-
cle for protein expression/delivery to target various diseases and
tissues.
MSC AS A VACCINE PLATFORM
An MSC delivery platform is similar to that of a DNA vaccine
or cellular vaccine in that the antigen is expressed through DNA
transfection and delivered by an ex vivo cultured cell. It may be
that this MSC strategy improves on problems that have occurred
with DNA and DC-based vaccinations. There are two basic uses
of such an MSC platform, as an anti-cancer therapeutic vaccine
or as an anti-microbial prophylactic vaccine, discussed in more
detail below.
ANTI-CANCER THERAPEUTIC VACCINES
MSC have been studied as a delivery vehicle for anti-cancer ther-
apeutics due to their innate tendency to home to tumor microen-
vironments, and is thoroughly reviewed in Loebinger and Janes
(2010). MSC have also been used to promote apoptosis of tumori-
genic cells through the expression of IFNα or IFNγ (Li et al., 2006;
Ren et al., 2008). Additionally, MSC have recently been explored
as novel, vaccine platform in the prevention and inhibition of
tumorigenesis and metastasis. A unique study by Wei et al. exam-
ined the use of human papilloma virus (HPV)-immortalized
MSC that express the HPV proteins E6/E7 combined with a mod-
ified E7 fusion protein vaccine in a mouse tumor model where
metastatic fibrosarcoma cells were administered (Wei et al., 2011).
This group found that only when mice were immunized with
both the E7-expressing MSC and modified E7 protein vaccine
did mice show a decrease in tumor growth, and an E7-specific
antibody response. Mice receiving either MSC or protein vaccine
alone were not able to raise an anti-E7 response or inhibit tumor
growth of metastatic sarcoma. The limitation of this interesting
approach is that it can only be used as an anti-cancer therapeutic
and not as a universal cancer preventative, as individual tumors
have unique antigen expression. In addition, a long-term safety
examination of these immortalized MSC/protein vaccine therapy
in cancer-free mice is warranted. Although these immortalized
MSC were previously determined to be non-tumorigenic (Hung
et al., 2004), they persisted inmice longer than 21 days, unlike pri-
mary MSC (i.e., non-immortalized) which are only detectable for
a very short time after administration (Gao et al., 2001; Abraham
Frontiers in Cellular and Infection Microbiology www.frontiersin.org November 2012 | Volume 2 | Article 140 | 3
Tomchuck et al. MSC as a vaccine platform
et al., 2004; Ohtaki et al., 2008; Prockop, 2009). Thus, there may
be unforeseen outcomes in the long term (i.e., outcompeting with
endogenous MSC and differing immunomodulatory abilities,
which were not assessed in this study) with the use of immortal-
ized MSC even if they prove to be non-malignant. Other studies
have indicated that immortalized MSC can become tumorigenic,
and thus must be carefully studied to determine if they are indeed
safe for use (Rubio et al., 2005; Phinney and Prockop, 2007;
Tolar et al., 2007).
ANTI-MICROBIAL PROPHYLACTIC VACCINES
To date, the ability of MSC to be used as a novel platform
for a prophylactic vaccine for infectious disease has not been
published. To demonstrate this proof of concept, research con-
ducted by our group has shown that MSC, modified to express
a foreign antigen, are sufficient to elicit an antibody-mediated
immune response without the need for additional adjuvants
or boosting. In our studies, using a plasmid encoding gp120,
the glycoprotein from HIV, MSC can be readily modified to
secrete a foreign, viral antigen, and stimulate antigen-specific
antibody production in vivo. These transfected MSC transiently
express high levels of gp120 protein intracellularly, with the peak
expression 1 day post-transfection (Figures 2A,B). Following
transfection, MSC then secrete significant amounts of gp120
protein over 1–4 days in culture (Figure 2C). These expres-
sion levels can be controlled in a dose-dependent manner based
on the amount of plasmid used during the transfection pro-
cess. For example, by 2 days post-transfection MSC secreted
2.11 ± 0.73, 6.22 ± 2.98, or 5.41 ± 2.25μg gp120 per million
cells when transfected with 2.5, 5, or 7.5μg of vector, respec-
tively. Four days post-transfection these cells secreted 2.75 ±
0.81, 5.04 ± 0.252, or 12.03 ± 0.77μg gp120, respectively. The
levels of antigen produced in this transient transfection are suf-
ficient to induce an immunological response from a vaccine
standpoint.
To examine the ability of transfected MSC to elicit an
in vivo antibody response, C57Bl/6 mice were immunized once
by intraperitoneal (IP), subcutaneous (SC) or intramuscular
FIGURE 2 | MSC can be modified to express viral protein gp120.
MSC derived from the bone marrow of C57Bl/6 mice were isolated
and validated by the Tulane Center for Stem Cell Research and
Regenerative Medicine (New Orleans, LA) as previously described
(Ripoll and Bunnell, 2009). A total of 1 × 106 MSC were transfected by
electroporation using the Invitrogen Neon system (Carlsbad, CA) with
2.5, 5, or 7.5μg pSWTK-gp120, or empty vector, pSWTK (generously
provided by Dr. V. S. Kalyanaraman of ABL Inc., Kensington, MD)
according to the manufacturer’s instructions. (A) Gp120
immunofluorescence staining of MSC transfected with 5μg pSWTK or
pSWTK-gp120 1 or 7 days post-transfection, and controls using
secondary (2◦) antibody only, was carried out as previously described at
63X (Tomchuck et al., 2008). (B) Western blot analysis of corresponding
cell lysates (approximately 25μg of protein) were probed with
anti-gp120 as previously described (Lamarca et al., 2008). (C) 1 × 105
transfected MSC were incubated 1–4 days and the harvested cell
culture supernatants were analyzed by an HIV-1 gp120 ELISA according
to the manufacturer’s instructions (ABL Inc.) Data are presented as the
mean ± standard error of the mean and analyzed by One Way ANOVA
using the Tukey’s post hoc test (GraphPad Prism Version 4). Statistical
significance was determined by comparing pSWTK-gp120 and pSWTK
groups. ∗p < 0.05; ∗∗p < 0.01; ∗∗∗p < 0.001.
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(IM) routes using either MSC-gp120 or purified gp120. Since
transplanted MSC persist only for a few days at most in vivo
(Gao et al., 2001; Abraham et al., 2004; Ohtaki et al., 2008;
Prockop, 2009), 5μg of gp120 was chosen as an amount equiv-
alent to antigen secreted by MSC-gp120, transfected with 7.5μg
of pSWTK-gp120. Similar to other published studies, a single
gp120 protein immunization produced no detectable serum anti-
bodies by 17 days post-immunization (Jankovic et al., 1997;
McCormick et al., 2001; Lamalle-Bernard et al., 2006) (Figure 3).
FIGURE 3 | Modified MSC expressing gp120 promote serum anti-gp120
antibody responses in mice after parenteral immunization. Groups of
five female C57Bl/6 mice 6–8 weeks underwent a single immunization with
1 × 106 MSC transfected with 7.5μg pSWTK-gp120 (MSC-gp120; solid
lines) 16h post-transfection or 5μg purified gp120 (a vector-corresponding
recombinant protein provided by Dr. V. S. Kalyanaraman; broken lines), with
naïve mice serving as a control (black). MSC and gp120 were diluted in
DPBS and administered with a 0.5ml syringe to deliver 100μl per dose for
intraperitoneal and subcutaneous injection, or 50μl per dose for
intramuscular injection. Mice were sacrificed 17 days post-immunization
and sera collected. An ELISA for serum anti-gp120 IgG antibodies graphed
as 405nm absorbance versus sera dilution was preformed as previously
described (Norton et al., 2011). Animal studies were approved by the Tulane
University Institutional Animal Care and Use Committee.
Mice immunized with MSC expressing an empty vector also did
not elicit serum anti-gp120 responses above sera of näive mice
(data not shown). However, all mouse groups receiving an MSC-
gp120 immunization developed high-titer serum anti-gp120 IgG
antibodies regardless of IP, SC, or IM delivery.
EVIDENCE THAT MSC CAN PROMOTE ADAPTIVE IMMUNITY
Our studies with gp120 antigen, in addition to the report by Wei
et al., indicate that modified MSC can deliver antigen for protec-
tive vaccination against an infectious disease or cancer, in support
of our hypothesis. However, the exact mechanisms whereby MSC
might be directly influencing the generation of immune responses
are unknown. Our experimental data suggest a pertinent role for
MSC as more than just a delivery vehicle; gp120 alone (at the
estimated dose of MSC-gp120 expression) elicited undetectable
humoral responses, similar to previous studies (Jankovic et al.,
1997; McCormick et al., 2001; Lamalle-Bernard et al., 2006),
while MSC-gp120 induced significant anti-gp120 antibodies after
a single immunization.
While MSC are primarily touted for their immunosuppres-
sive properties, several published reports have also directly shown
that MSC promote adaptive immunity. Table 1 lists publica-
tions in which investigators reported MSC-driven activation of
T-cells and B-cell responses, mainly through cytokine secretion
or antigen-presentation in a variety of experimental settings. In
co-cultures, MSC enhanced B-cell proliferation, IL-6 expression,
and IgG-secreting plasma cell formation in vitro; these B-cell
responses could be further augmented with MSC combined with
a TLR agonist (lipopolysaccharide or CpG DNA) (Rasmusson
et al., 2007; Traggiai et al., 2008). MSC pulsed with tetanus
toxoid promoted the proliferation and cytokine expression (IL-
4, IL-10, and IFNγ) of a tetanus toxoid-specific CD4 T-cell
line (Majumdar et al., 2003; Stagg, 2007; Francois et al., 2009).
Similarly, MSC cultured in low ratios (1:100) with lymphocytes
in the presence of antigen improved lymphocyte proliferation
and CD4 Th17 subset formation, which was partially IL-6 and
Table 1 | Evidence that MSC can promote adaptive immunity.
MSC PROMOTION OF ADAPTIVE IMMUNITY
Experimental setting Defined MSC function Immunologic outcome References
In vitro culture of B-cells/splenocytes and
MSC ± TLR agonists (LPS, CpG)
IL-6 secretion B-cell proliferation
IgG secretion
Rasmusson et al., 2007
Traggiai et al., 2008
In vitro culture of antigen-specific CD4
T-cells, MSC, and antigen
MHC-II antigen-presentation
IL-6, TGFβ secretion
T-cell proliferation IL-4, IL-10, IFNγ
secretion
Lymphocyte proliferation, Th17 cells
Majumdar et al., 2003
Liu et al., 2009
In vitro cultures of splenocytes and MSC;
Mouse models of collagen-induced arthritis
IL-6 secretion Th1 cells
lymphocyte proliferation, IL-6, IL-17
secretion
Djouad et al., 2005
Chen et al., 2009
IFNγ stimulation (moderate levels) during
in vitro cultures of T-cells and MSC; Mouse
model of systemic lupus erythematosus
MHC-I/II
antigen-presentation,
phagocytosis
CD4 and CD8 T-cell proliferation,
Anti-tumor CD8+ CTLs
Majumdar et al., 2003;
Chan et al., 2006; Stagg,
2007; Francois et al.,
2009; Schena et al., 2010
In vitro culture with apoptotic cells and
CD4 T-cells
MHC-II expression,
IL-6 secretion
Th17 cells Tso et al., 2010
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TGFβ-dependent (Liu et al., 2009). MSC have also been found to
express MHC-I and cross-present antigen for expansion of CD8
T-cells both in vitro and in vivo (Majumdar et al., 2003; Stagg,
2007; Francois et al., 2009).
MSC immunoregulation has also been found to be dependent
upon external signals. In the presence of inflammatory cytokines
or stimulants, MSC therapy, which was previously suppres-
sive, can become immunostimulatory. For example, MSC treated
with specific pathogen-associated molecular pattern (PAMP)
molecules can become either anti- or pro-inflammatory, depend-
ing on the PAMP with which they are treated in vitro (Tomchuck
et al., 2008; Waterman et al., 2010), reviewed more thoroughly
in (Bunnell et al., 2010; Le Blanc and Mougiakakos, 2012).
Djouad et al. found that during collagen-induced arthritis, an
inflammatory disease setting, transplantation of allogeneic MSC
enhanced Th1 immune responses, and IL-6 secretion, which was
mimicked in vitro by direct TNFα stimulation of MSC (Djouad
et al., 2005). A similar study also foundMSC administration exac-
erbated collagen-induced arthritis disease and amplified spleno-
cyte secretion of IL-6 and IL-17 (Chen et al., 2009). Furthermore,
pre-treatment of MSC with IFNγ (within a moderate range)
upregulates MHC-I and II expression and improves antigen
phagocytosis and presentation capabilities, thereby stimulating
CD4 and CD8 T-cell proliferation and generation of anti-tumor
CD8+ cytotoxic T-lymphocytes (CTLs) (Majumdar et al., 2003;
Chan et al., 2006; Stagg, 2007; Francois et al., 2009; Schena
et al., 2010). In another study, co-culture of MSC with apoptotic
cells, which mimics conditions of rheumatoid arthritis, induced
Th17 cells through IL-6 expression on MHC-II expressing MSC
(Tso et al., 2010).
These studies support our hypothesis that MSC can be used
to as a novel vaccination platform generating protective immu-
nity. They also suggest mechanisms that may be involved during
modified MSCs vaccination besides antigen delivery, including
cytokine secretion and antigen presentation (Figure 1B). While
not always explicitly required, the enhanced promotion of immu-
nity by MSC seen with cytokine or PAMP treatment indicates
that vaccine antigens that are highly immunogenic may direct a
more immunostimulatory phenotype of the MSC used for vac-
cination. For example, MSC modified to express a bacterial or
viral TLR ligand, in conjunction with other pertinent micro-
bial antigens, may be able to promote even higher levels of
protective antigen-specific immunity than microbial antigens by
themselves. It is also tempting to speculate that the modification
process combined with the expression of any immunogenic anti-
gen may provide some sort of “inflammatory” signal to the MSC
that could positively impact subsequent generation of vaccination
responses.
KNOWLEDGE GAPS AND FUTURE DIRECTIONS
The idea of MSC as a novel vaccine approach is clearly still
in its infancy and many knowledge gaps exist before this strat-
egy could ever be practically realized. In particular, while the
potential for MSC as a delivery system is tremendous, in depth
evaluation is needed into how many foreign or cancer antigens
can be effectively expressed by MSC. It will also be important
to perform a more detailed analysis on the impact of MSC
vaccination responses on antigen-specific immunity, including
humoral and cellular responses, induction of long-term memory,
etc. As described above, it will be critical to establish the mech-
anism(s) whereby modified MSC promote vaccine immunity.
While clearly MSC can effectively express and secrete vac-
cine antigens, these MSC might be more directly enhancing
immune responses through antigen presentation and/or inflam-
matory cytokine expression, as seen in previous non-vaccination
studies (Table 1). It is particularly exciting that MSC may be
able to enhance immune responses by direct antigen presen-
tation to T-cells. However, to date there has been no exam-
ination of whether this happens during a vaccination setting
and future scientific examination of MSC for antigen presen-
tation of vaccine antigens is warranted. This possible ability of
MSC to act as conditional APCs, but with less risk for GvHD,
makes them an attractive alternative to other cellular-based
vaccinations.
One aspect of transfected MSC for vaccination is the difference
in immunologic responses between stable-transfection strategies
versus transient-transfection. Logic would indicate that a tran-
sient transfection might offer the best safety profile, without the
worry of cell persistence, tumorigenicity etc. In addition, since
MSC can have alternative immunomodulatory functions during
inflammatory conditions and home to inflamed sites (at least
when given intravenously), it will also be important to ascertain
how effective an MSC vaccination will be when the host recipi-
ent is under any inflammatory disease setting. Therefore, a careful
examination of the safety of MSC vaccination will also need to be
evaluated.
CONCLUDING REMARKS
In summary, MSC have unique abilities that could enable their
use as a novel vaccine delivery method. These include (1) pro-
tection from allogeneic host responses (GvHD), (2) ease of
production attributes including ability to be expanded and mod-
ified ex vivo for transient or stable transfection before in vivo
administration, (3) ability to act as delivery vehicle/depot for
antigen release over several days, and (4) initiation and possibly
direct stimulation of antigen specific immune responses to these
antigens in vivo.
Such a MSC platform is theoretically capable of express-
ing hundreds of proteins, thereby generating a broad array of
epitopes with correct post-translational processing, mimicking
natural infection. By stimulating immunity to a combination
of epitopes, it may be possible to develop prophylactic and
even therapeutic vaccines to major global health diseases, like
HIV, where traditional vaccination approaches have failed. While
modified MSC delivery is unconventional, their unique prop-
erties may indeed be able to serve as an innovative vaccine
platform.
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